Cobomarsen (MRG-106) - an HSP90 inhibitor

- Cobomarsen is a chemically synthesized, phosphorothioate oligonucleotide, 14 nucleotides in length, that targets a unique region of the heat shock protein 90 (HSP90).
- Phase II trials in CTCL, DLBCL, CLL, and ATLL.
- Parts C through E not shown.

Conclusions

- Cobomarsen is well tolerated in CTCL and ATLL patients treated to date.
- No SAEs deemed related to study drug with two SAEs in two patients (Grade 3 worsening pruritus and Grade 3 seizure disorder).

References and Acknowledgments

- American Society of Clinical Oncology (ASCO) Annual Meeting 2018
- Abstract #2511

Cobomarsen Decreases Activation and Proliferation Status of Circulating Tumor Cells Leading to Stable Disease in Advanced Cutaneous T-cell Lymphoma

- Cobomarsen decreases activation and proliferation status of circulating tumor cells in CTCL patients leading to stable disease in advanced cutaneous T-cell lymphoma.
- Reduction in gene expression changes correlated with lesion drug levels including one that targets ALKBH5.
- Partial response (PR) for patient 101 at 4 months in duration.

Quality of Life Improvement, as Measured by Minimally Important Changes in 32 Patients out of a Total of 96

- Minimally important changes (MIC) represent a score change where >50% of patients have achieved an MIC with cobomarsen.
- 29 (71%) of 96 evaluable patients (n=18) had ≥50% mSWAT in CTCL Patients who received Cobomarsen.